Evaluation of nemvaleukin for platinum-resistant ovarian cancer will be terminated based on OS data from an interim analysis ...
Nemvaleukin alfa is an investigational engineered fusion protein composed of modified interleukin-2 (IL-2) and the high-affinity IL-2 alpha receptor chain.
Mural Oncology's stock plummeted 57% after halting the Phase 3 ARTISTRY-7 trial for nemvaleukin alfa. Click here to read an ...
A Waltham company pulled the plug on a Phase 3 cancer trial, while a different Waltham company continued its leadership ...
Clinical Trials Arena on MSN5d
MSD’s subcutaneous Keytruda non-inferior to IV version of blockbuster drugCompared to the IV infusion of the blockbuster cancer drug Keytruda, subcutaneous Keytruda can cut the time spent in ...
Mural Oncology (NASDAQ:MURA – Get Free Report) was downgraded by stock analysts at Raymond James from a “strong-buy” rating ...
Mural Oncology (NASDAQ:MURA – Get Free Report) had its target price lowered by equities researchers at HC Wainwright from $18 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback